{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:08:30Z","timestamp":1788797310276,"version":"build-2803163510"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Diabetic kidney disease (DKD) has emerged as the primary driver of kidney failure across the Asia-Pacific region. Thus, therapeutic interventions capable of effectively slowing the progression of chronic kidney disease (CKD) and reducing concomitant cardiovascular risk are of critical strategic importance. Finerenone, a novel non-steroidal mineralocorticoid receptor antagonist (nsMRA) approved for the treatment of DKD, exerts cardiorenal protective effects by selectively inhibiting the overactivation of the mineralocorticoid receptor (MR)\u2014a key mediator of pathological inflammatory and fibrotic processes underlying renal and cardiac injury. A consistent finding across major clinical trials, including FIDELIO-DKD, FIGARO-DKD, and the pooled FIDELITY analysis, is the \u201cpotentially enhanced\u201d (based on post-hoc subgroup analyses) therapeutic efficacy of finerenone in Asian, predominantly Chinese, patient populations. This review synthesizes emerging evidence indicating a distinct, potentially superior therapeutic response (based on available subgroup analyses) in Asian cohorts compared to global populations, alongside potential genetic and environmental factors contributing to this phenomenon. Additionally, we address the associated safety profile of hyperkalemia in Asian patients. We contend that this risk is manageable through structured monitoring and should not preclude clinicians from utilizing this high-impact therapy. Ultimately, this review positions finerenone as a crucial and effective intervention for Asian patients with high cardiorenal risk, provided that potassium homeostasis is proactively managed.<\/jats:p>","DOI":"10.1093\/ckj\/sfag279","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:52:23Z","timestamp":1787140343000},"source":"Crossref","is-referenced-by-count":0,"title":["Finerenone in Asian patients with diabetic kidney disease: evaluating the evidence for \u201cbetter efficacy\u201d"],"prefix":"10.1093","volume":"19","author":[{"given":"Siqian","family":"Gong","sequence":"first","affiliation":[{"name":"Peking University People\u2019s Hospital Department of Endocrinology and Metabolism, , Beijing ,","place":["China"]},{"name":"Beijing Key Laboratory of Innovative Drug and Device Translation in Endocrine and Metabolic Diseases , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3262-2168","authenticated-orcid":false,"given":"Linong","family":"Ji","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital Department of Endocrinology and Metabolism, , Beijing ,","place":["China"]},{"name":"Beijing Key Laboratory of Innovative Drug and Device Translation in Endocrine and Metabolic Diseases , Beijing ,","place":["China"]},{"name":"Peking University Diabetes Center , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"2026090711161694900_bib1","doi-asserted-by":"publisher","first-page":"872","DOI":"10.2215\/CJN.0000000909","article-title":"Implementation of established global guidelines in the management of CKD in patients with type 2 diabetes in Asia","volume":"21","author":"Agarwal","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026090711161694900_bib2","doi-asserted-by":"publisher","first-page":"e13566","DOI":"10.1111\/1753-0407.13566","article-title":"Renal effects and safety between Asian and non-Asian chronic kidney disease and type 2 diabetes treated with nonsteroidal mineralocorticoid antagonists","volume":"16","author":"Xu","year":"2024","journal-title":"J Diabetes"},{"key":"2026090711161694900_bib3","doi-asserted-by":"publisher","first-page":"e70031","DOI":"10.1111\/nep.70031","article-title":"Executive summary of the Asian Pacific Society of Nephrology Clinical Practice Guideline on diabetic kidney disease-2025 update","volume":"30","author":"Liew","year":"2025","journal-title":"Nephrology"},{"key":"2026090711161694900_bib4","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD work group","year":"2024","journal-title":"Kidney Int"},{"key":"2026090711161694900_bib5","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2026090711161694900_bib6","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026090711161694900_bib7","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1159\/000531997","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes: the FIDELIO-DKD subgroup from China","volume":"9","author":"Zhang","year":"2023","journal-title":"Kidney Dis"},{"key":"2026090711161694900_bib8","doi-asserted-by":"publisher","first-page":"1568438","DOI":"10.3389\/fendo.2025.1568438","article-title":"Impact of finerenone on chronic kidney disease progression in Chinese patients with type 2 diabetes: a FIGARO-DKD subgroup analysis","volume":"16","author":"Li","year":"2025","journal-title":"Front Endocrinol"},{"key":"2026090711161694900_bib9","doi-asserted-by":"publisher","first-page":"109213","DOI":"10.1016\/j.jdiacomp.2025.109213","article-title":"Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: a FIDELITY analysis by baseline kidney function","volume":"40","author":"Katayama","year":"2025","journal-title":"J Diabetes Complications"},{"key":"2026090711161694900_bib10","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/jdi.70023","article-title":"Effectiveness of finerenone in Chinese patients with type 2 diabetes mellitus and chronic kidney disease with microalbuminuria: a retrospective real-world study","volume":"16","author":"Wu","year":"2025","journal-title":"J Diabetes Invest."},{"key":"2026090711161694900_bib11","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"2026090711161694900_bib12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.2215\/CJN.0000000865","article-title":"Impact of simultaneous initiation of finerenone and empagliflozin on urinary albumin-to-creatinine ratio in Asia: pre-specified analysis of CONFIDENCE","volume":"21","author":"Agarwal","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026090711161694900_bib13","doi-asserted-by":"publisher","first-page":"e70137","DOI":"10.1111\/jch.70137","article-title":"Associations of genetic variations in the NR3C2 with salt sensitivity, longitudinal blood pressure changes, and incidence of hypertension in Chinese adults","volume":"27","author":"Wang","year":"2025","journal-title":"J Clin Hypertens"},{"key":"2026090711161694900_bib14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40262-019-00820-x","article-title":"Population Pharmacokinetic and exposure-response analysis of finerenone: insights based on Phase IIb data and simulations to support dose selection for pivotal trials in type 2 diabetes with chronic kidney disease","volume":"59","author":"Snelder","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"2026090711161694900_bib15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.4093\/dmj.2026.0306","article-title":"Finerenone in Asian patients with type 2 diabetes mellitus and albuminuric chronic kidney disease: from evidence to implementation","volume":"50","author":"Yamanouchi","year":"2026","journal-title":"Diabetes Metab J"},{"key":"2026090711161694900_bib16","doi-asserted-by":"publisher","first-page":"e076444","DOI":"10.1136\/bmjopen-2023-076444","article-title":"Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post-hoc analysis of two phase 3, multicentre, double-blind trials","volume":"14","author":"Bansal","year":"2024","journal-title":"BMJ Open"},{"key":"2026090711161694900_bib17","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1007\/s13300-025-01796-7","article-title":"Pillar risk-based treatment for chronic kidney disease in people with type 2 diabetes: a narrative review","volume":"16","author":"Cheng","year":"2025","journal-title":"Diabetes Ther"},{"key":"2026090711161694900_bib18","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1253\/circj.CJ-16-0122","article-title":"A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and\/or chronic kidney disease","volume":"80","author":"Sato","year":"2016","journal-title":"Circ J"},{"key":"2026090711161694900_bib19","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.2337\/dc19-2419","article-title":"Efficacy of modern diabetes treatments DPP-4i, SGLT-2i, and GLP-1RA in white and Asian patients with diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Gan","year":"2020","journal-title":"Diabetes Care"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag279\/70722537\/sfag279.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/9\/sfag279\/70722537\/sfag279.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/9\/sfag279\/70722537\/sfag279.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:16:23Z","timestamp":1788794183000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag279\/8766987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag279","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,20]]},"article-number":"sfag279"}}